Clinical Commander

Back to dossier
cardio.atrial_flutter.endurance-athlete.v1PRODUCTION
cardio.atrial_flutter.endurance-athlete.v1

Atrial flutter in the long-term endurance athlete

cardiologyacuteadult
Hard-required inputs
0 / 15
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Endurance-athlete AFL: chronic high-volume training → LA dilation + vagal bradycardia + atrial fibrosis → AFL substrate. Acute: cautious rate control (BB short-acting low-dose given baseline bradycardia; diltiazem if BB intolerance), low DCCV threshold for symptomatic athletes, AC per CHA2DS2-VASc with sport-trauma considerations. Long-term: training-VOLUME REDUCTION is anchor intervention; early CTI ablation for typical AFL (>95% success per HRS/EHRA/ECAS 2017); OSA + alcohol screen + treatment

Inputs
2
Actions
0
Advance rule
Set
Advance when

endurance-athlete AFL phenotype framed

Patient inputs (16)

High prevalence in middle-aged endurance males via increased neck circumference + supine training adaptations; treating OSA reduces AFL/AF recurrence by 30-50% (CAPPS PMID 27744102)

Risk concentrated in 40-65 y middle-aged males with cumulative endurance years; pediatric / adolescent cases rare and route to peds-specific dossier

Strong male predominance (M:F ≈ 5:1) in endurance-induced AFL/AF; female sex = +1 CHA2DS2-VASc; informs AC threshold + ablation candidacy

Dose-response: >5-10 h/wk for >10 y carries 2-5× AFL/AF risk; quantifies substrate severity; targets training-volume reduction as primary lifestyle Rx (Andersen 2013 PMID 23736857; Mont 2002 PMID 12099811)

Athlete's resting HR commonly 40-55 in NSR; BB titration must be cautious + short-acting; informs CCB vs BB choice for rate control

Flutter rate; rate-control target 80-110 (lenient) vs <80 (strict) per RACE-II; very high rates (>180) suggest accessory bypass tract — re-screen WPW

Excludes thyrotoxicosis-precipitated AFL (would route to cardio.atrial_flutter.thyroid-related.v1); athletes occasionally on supraphysiologic T4 for performance

Endurance cohort often has higher alcohol prevalence; cross-link to cardio.atrial_flutter.alcohol-related.v1 if heavy; stimulant supplements (caffeine, ephedrine-class pre-workouts, anabolic steroids) can precipitate

Confirms flutter morphology (typical CTI-dependent counterclockwise sawtooth in II/III/aVF — most common — vs atypical LA flutter); QT for medication safety; ischemic ST changes

LA volume index (athlete vs pathologic dilation cutoff LAVI >34-40 mL/m²); LV mass index; RV strain; valvular; rule out HCM/ARVC masquerade; bicuspid aortic valve screen (sport-related sudden death cohort)

eGFR for DOAC dosing; CBC for anemia (athletes occasionally over-trained anemia); BUN/Cr; Mg + K (training-induced electrolyte shifts can drive arrhythmia)

Rule out demand ischemia at high flutter rates; small troponin rise common post-marathon but persistent + clinical concern → ACS evaluation

SBP <90 with flutter RVR = DCCV; athletes often have low-normal baseline SBP (90-110); informs vasoactive thresholds

Often 0-1 in this cohort (young male, no DM/HTN/HF) — AC threshold + duration decisions; thresholds in young male athletes weigh trauma + lifestyle vs stroke

HAS-BLED + active sport increases trauma-related bleed risk on AC; informs DOAC vs no AC after CV; LAAO discussion in selected

Distinguishes athlete's heart (no LGE, regression on deconditioning) from pathologic CMP (HCM, ARVC, sarcoid, prior myocarditis); also assesses LA scar burden which predicts ablation success

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningwpw_pattern_with_rapid_aflutter_conduction_in_athlete
    WPW or pre-excitation pattern on resting ECG + flutter with ventricular rates >250 — risk of 1:1 conduction with ventricular pre-excitation degenerating to VF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereaflutter_with_tachycardia_mediated_cardiomyopathy_in_athlete
    Sustained AFL with rapid ventricular response (>130 sustained) + new severe LV dysfunction (EF <40) in previously high-functioning endurance athlete → tachycardia-mediated cardiomyopathy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereaflutter_with_syncope_in_endurance_athlete
    AFL accompanied by syncope or pre-syncope — competition-related or training-related — must rule out concomitant channelopathy, HCM, ARVC, ischemia given young athlete sudden-death risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremajor_bleed_on_anticoagulation_in_active_athlete
    Major bleeding (GI, intracranial, traumatic from training/competition) on AC in active endurance athlete — common given trauma + exertion-related vascular fragility
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateablation_failure_or_recurrence_within_first_year
    CTI ablation performed but AFL recurs within 12 mo OR ablation acute success not achieved (rare for typical AFL — should occur <5%)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Endurance-athlete AFL — cautious low-dose BB (or diltiazem) given baseline bradycardia + low DCCV threshold + early CTI ablation + training-volume reduction anchor + OSA/alcohol screen — ACC/AHA 2024 (PMID 38753446) + ESC 2020 Sports Cardiology (PMID 32860412)
axis: aflutter_endurance_athlete_pathway
Selected axis "Endurance-athlete AFL — cautious low-dose BB (or diltiazem) given baseline bradycardia + low DCCV threshold + early CTI ablation + training-volume reduction anchor + OSA/alcohol screen — ACC/AHA 2024 (PMID 38753446) + ESC 2020 Sports Cardiology (PMID 32860412)" by default fallback (first axis)
  • esmolol
    first line
    beta_blocker_b1_ultrashort
    500 mcg/kg IV bolus (or skip in stable patient) then 25-100 mcg/kg/min infusion titrate to HR 80-110 • IV • continuous infusion
    triggers: acute_rate_control_with_baseline_bradycardia_concern, titratable_bb_for_athlete_low_resting_hr
    PREFERRED acute IV BB in athlete cohort — ultra-short half-life (~9 min) allows fine titration if hemodynamics shift; respects baseline bradycardia; ACC/AHA 2024 Class I rate control
    rxcui 203222
  • metoprolol_tartrate
    first line
    beta_blocker_b1_selective
    12.5-25 mg PO BID low-dose initial; titrate cautiously to HR 80-110 in NSR <90 • PO • BID
    triggers: oral_rate_control_in_endurance_athlete
    Low-dose b1-selective preserves exercise capacity better than non-selective; cautious because baseline resting HR 40-55 in athletes; ACC/AHA 2024 Class I
    rxcui 6918
  • diltiazem
    first line
    non_dhp_ccb
    0.25 mg/kg IV bolus (max 20 mg) then 5-15 mg/h infusion; PO 120-360 mg daily extended release • IV/PO • continuous or daily ER
    triggers: bb_intolerance_from_baseline_bradycardia, asthma_or_reactive_airway_avoidance
    Alternative when BB poorly tolerated due to athlete's baseline bradycardia or reactive airways; ACC/AHA 2024 Class I rate control; avoid in EF <40
    rxcui 3443
  • apixaban
    first line
    doac_factor_xa_direct
    5 mg PO BID (2.5 mg BID if 2 of: age ≥80, wt ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: post_cardioversion_4_week_ac, long_term_ac_per_cha2ds2vasc_score_ge_1, planned_ablation_periprocedural
    PREFERRED AC — DOAC trumps warfarin in active-lifestyle athlete (no INR monitoring, no diet interference, slightly lower bleed); ARISTOTLE foundational (PMID 21870978); ACC/AHA 2024 (PMID 38753446) Class I
    rxcui 1364430
  • rivaroxaban
    first line
    doac_factor_xa_direct
    20 mg PO with food (15 mg if CrCl 15-50) • PO • once daily
    triggers: apixaban_unavailable, patient_prefers_once_daily
    Once-daily alternative DOAC; ROCKET-AF; ACC/AHA 2024
    rxcui 1114195
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg daily; INR target 2-3 • PO • daily
    triggers: mechanical_valve, severe_renal_failure_crcl_below_15, doac_intolerance_or_cost_barrier
    Reserve for mechanical valve / severe CKD / cost; INR + diet management onerous for endurance athletes
    rxcui 11289
  • amiodarone
    second line
    class_iii_antiarrhythmic
    150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h; oral 200-400 mg daily load then 100-200 mg maintenance • IV/PO • continuous + daily
    triggers: refractory_aflutter_with_lv_dysfunction, rhythm_control_when_ablation_delayed
    AVOID first-line in young endurance athlete — long-term pulmonary, thyroid, hepatic, ocular toxicity prohibitive over expected decades of life; reserve for bridge to ablation or LV dysfunction; ACC/AHA 2024 IIb
    rxcui 703
  • CTI ablation for typical AFL
    first line
    electrophysiology_procedure
    Single-session catheter ablation of cavotricuspid isthmus • procedural • one-time
    triggers: typical_cavotricuspid_dependent_aflutter_confirmed_by_eps, symptomatic_or_recurrent_or_athlete_preference_to_avoid_long_term_drug
    HRS/EHRA/ECAS 2017 (Calkins PMID 28506916) — >95% acute success for typical AFL; preferred earlier in young athlete to avoid decades of drug therapy + facilitate return to training
  • synchronized DCCV 50-100 J biphasic
    first line
    electrical_cardioversion
    50-100 J synchronized biphasic, escalate to 200 J • procedural • as needed
    triggers: symptomatic_aflutter_with_planned_return_to_training, hemodynamic_instability
    Low DCCV threshold in athlete cohort given desire to restore symptom-free training; 4-wk AC pre-CV if onset >48h or unclear; ACC/AHA 2024 Class I
  • training volume reduction to <5 h/wk submaximal × 3-6 mo trial
    first line
    lifestyle_substrate_modification
    Reduce weekly endurance hours to <5 h/wk + avoid prolonged events for 3-6 mo as substrate-reversal trial • lifestyle • sustained
    triggers: endurance_athlete_with_aflutter_or_af_substrate
    Andersen 2013 marathon cohort (PMID 23736857) + Mont 2002 (PMID 12099811) + Mohanty 2016 (PMID 27340861) — dose-response with reversibility; single most powerful long-term intervention in this cohort
  • CPAP for OSA if positive
    comorbidity specific
    osa_treatment
    Per sleep study titration • lifestyle/device • nightly
    triggers: osa_documented_on_sleep_study
    CAPPS-style cohorts show 30-50% AFL/AF recurrence reduction with effective OSA treatment; common comorbidity in middle-aged endurance males
  • alcohol cessation
    comorbidity specific
    lifestyle_substrate_modification
    Zero alcohol × 6 mo trial; reassess • lifestyle • sustained
    triggers: alcohol_intake_above_recommended_or_arrhythmia_after_drinking
    Alcohol-Abstinence trial (Voskoboinik NEJM 2020 PMID 31893513) — abstinence reduces AF recurrence; endurance cohort frequently moderate-heavy drinkers

outpatient playbook — drug actions (3)

  1. 1. post-ablation rate control if needed
    rxcui 6918
    metoprolol tartrate 12.5-25 mg PO BID per HR • PO • BID
    trigger: Post-ablation NSR maintenance or breakthrough
    ACC/AHA 2024
  2. 2. AC reassessment per CHA2DS2-VASc
    rxcui 1364430
    apixaban 5 mg BID per score; CONSIDER STOPPING if CHA2DS2-VASc 0-1 + sustained NSR + 4-wk post-CV/ablation complete • PO • BID
    trigger: Long-term per stroke risk; in young low-score athlete, AC may be discontinued after NSR sustained
    ACC/AHA 2024 — AC indication is per stroke risk, NOT per ablation success; CHA2DS2-VASc-driven decision
  3. 3. consider tapering BB once detrained + NSR sustained
    rxcui 6918
    taper metoprolol tartrate over 4-8 wk under cardiology supervision • PO • BID tapering
    trigger: NSR ≥6 mo + chamber regression + athlete tolerant
    Discontinue prophylactic drug if substrate reversed

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New palpitations, exertional intolerance, or unexpected drop in training power output in long-term endurance athlete (≥10 yr cumulative high-volume training) — AFL/AF likely; 12-lead ECG with atrial flutter pattern + echo showing LA dilation + LV mass increase + low resting HR (athlete's-heart substrate); Marathon / cycling / triathlon / cross-country skiing background ≥10 y + new-onset AFL/AF; often presents during taper or after very long event.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atrial flutter in the long-term endurance athlete** (cardio.atrial_flutter.endurance-athlete.v1).
Scope: Endurance-athlete AFL: chronic high-volume training → LA dilation + vagal bradycardia + atrial fibrosis → AFL substrate. Acute: cautious rate control (BB short-acting low-dose given baseline bradycardia; diltiazem if BB intolerance), low DCCV threshold for symptomatic athletes, AC per CHA2DS2-VASc with sport-trauma considerations. Long-term: training-VOLUME REDUCTION is anchor intervention; early CTI ablation for typical AFL (>95% success per HRS/EHRA/ECAS 2017); OSA + alcohol screen + treatment

No severity triggers fired against current inputs.

Plan

Regimen axis: **Endurance-athlete AFL — cautious low-dose BB (or diltiazem) given baseline bradycardia + low DCCV threshold + early CTI ablation + training-volume reduction anchor + OSA/alcohol screen — ACC/AHA 2024 (PMID 38753446) + ESC 2020 Sports Cardiology (PMID 32860412)**.
1. esmolol 500 mcg/kg IV bolus (or skip in stable patient) then 25-100 mcg/kg/min infusion titrate to HR 80-110 IV continuous infusion (beta_blocker_b1_ultrashort, first line) — PREFERRED acute IV BB in athlete cohort — ultra-short half-life (~9 min) allows fine titration if hemodynamics shift; respects baseline bradycardia; ACC/AHA 2024 Class I rate control
2. metoprolol_tartrate 12.5-25 mg PO BID low-dose initial; titrate cautiously to HR 80-110 in NSR <90 PO BID (beta_blocker_b1_selective, first line) — Low-dose b1-selective preserves exercise capacity better than non-selective; cautious because baseline resting HR 40-55 in athletes; ACC/AHA 2024 Class I
3. diltiazem 0.25 mg/kg IV bolus (max 20 mg) then 5-15 mg/h infusion; PO 120-360 mg daily extended release IV/PO continuous or daily ER (non_dhp_ccb, first line) — Alternative when BB poorly tolerated due to athlete's baseline bradycardia or reactive airways; ACC/AHA 2024 Class I rate control; avoid in EF <40
4. apixaban 5 mg PO BID (2.5 mg BID if 2 of: age ≥80, wt ≤60 kg, Cr ≥1.5) PO BID (doac_factor_xa_direct, first line) — PREFERRED AC — DOAC trumps warfarin in active-lifestyle athlete (no INR monitoring, no diet interference, slightly lower bleed); ARISTOTLE foundational (PMID 21870978); ACC/AHA 2024 (PMID 38753446) Class I
5. rivaroxaban 20 mg PO with food (15 mg if CrCl 15-50) PO once daily (doac_factor_xa_direct, first line) — Once-daily alternative DOAC; ROCKET-AF; ACC/AHA 2024
6. warfarin 5 mg daily; INR target 2-3 PO daily (vitamin_k_antagonist, comorbidity specific) — Reserve for mechanical valve / severe CKD / cost; INR + diet management onerous for endurance athletes
7. amiodarone 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h; oral 200-400 mg daily load then 100-200 mg maintenance IV/PO continuous + daily (class_iii_antiarrhythmic, second line) — AVOID first-line in young endurance athlete — long-term pulmonary, thyroid, hepatic, ocular toxicity prohibitive over expected decades of life; reserve for bridge to ablation or LV dysfunction; ACC/AHA 2024 IIb
8. CTI ablation for typical AFL Single-session catheter ablation of cavotricuspid isthmus procedural one-time (electrophysiology_procedure, first line) — HRS/EHRA/ECAS 2017 (Calkins PMID 28506916) — >95% acute success for typical AFL; preferred earlier in young athlete to avoid decades of drug therapy + facilitate return to training
9. synchronized DCCV 50-100 J biphasic 50-100 J synchronized biphasic, escalate to 200 J procedural as needed (electrical_cardioversion, first line) — Low DCCV threshold in athlete cohort given desire to restore symptom-free training; 4-wk AC pre-CV if onset >48h or unclear; ACC/AHA 2024 Class I
10. training volume reduction to <5 h/wk submaximal × 3-6 mo trial Reduce weekly endurance hours to <5 h/wk + avoid prolonged events for 3-6 mo as substrate-reversal trial lifestyle sustained (lifestyle_substrate_modification, first line) — Andersen 2013 marathon cohort (PMID 23736857) + Mont 2002 (PMID 12099811) + Mohanty 2016 (PMID 27340861) — dose-response with reversibility; single most powerful long-term intervention in this cohort
11. CPAP for OSA if positive Per sleep study titration lifestyle/device nightly (osa_treatment, comorbidity specific) — CAPPS-style cohorts show 30-50% AFL/AF recurrence reduction with effective OSA treatment; common comorbidity in middle-aged endurance males
12. alcohol cessation Zero alcohol × 6 mo trial; reassess lifestyle sustained (lifestyle_substrate_modification, comorbidity specific) — Alcohol-Abstinence trial (Voskoboinik NEJM 2020 PMID 31893513) — abstinence reduces AF recurrence; endurance cohort frequently moderate-heavy drinkers

Setting playbook (outpatient) — Long-term cardiology + sport-cardiology + EP coordination; post-ablation surveillance; return-to-competition decision; AC reassessment per CHA2DS2-VASc + sport-trauma; chamber regression surveillance with detraining; lifestyle anchor maintenance
13. post-ablation rate control if needed metoprolol tartrate 12.5-25 mg PO BID per HR PO BID — Post-ablation NSR maintenance or breakthrough (ACC/AHA 2024)
14. AC reassessment per CHA2DS2-VASc apixaban 5 mg BID per score; CONSIDER STOPPING if CHA2DS2-VASc 0-1 + sustained NSR + 4-wk post-CV/ablation complete PO BID — Long-term per stroke risk; in young low-score athlete, AC may be discontinued after NSR sustained (ACC/AHA 2024 — AC indication is per stroke risk, NOT per ablation success; CHA2DS2-VASc-driven decision)
15. consider tapering BB once detrained + NSR sustained taper metoprolol tartrate over 4-8 wk under cardiology supervision PO BID tapering — NSR ≥6 mo + chamber regression + athlete tolerant (Discontinue prophylactic drug if substrate reversed)

Non-pharmacologic actions:
- Return-to-competitive endurance only after 3-6 mo demonstrated NSR or post-ablation clearance (ESC 2020 PMID 32860412)
- Maintain reduced training volume long-term (<5 h/wk submaximal continues if substrate reversal incomplete)
- OSA treatment adherence lifelong if positive
- Alcohol moderation continued
- EP follow-up post-ablation: smartwatch surveillance + symptom journal
- Cardiac rehab maintenance if structural disease
- Sport-psych for athletic identity transitions

AVOID / contraindication checks:
- Bb_cautious_initiation_with_athlete_baseline_bradycardia_resting_hr_below_50
- Avoid_amiodarone_first_line_in_young_athlete_long_term_toxicity (ACC/AHA 2024 IIb)
- Diltiazem_avoid_if_ef_below_40 (ACC/AHA 2022 HF)
- Doac_renal_dose_adjustment_per_egfr_athlete_low_baseline_cr (ESC 2024 PMID 39050851)
- Decision:early_cti_ablation_preferred_over_long_term_drug_in_young_athlete (HRS/EHRA/ECAS 2017 PMID 28506916)
- Decision:training_volume_reduction_is_anchor_long_term_intervention (Andersen 2013 PMID 23736857)
- Decision:osa_treatment_reduces_recurrence_30_to_50pct_screen_aggressively
- Decision:ac_4wk_post_cv_mandatory_long_term_per_cha2ds2vasc_with_sport_trauma_weighting
- Dccv_low_threshold_in_symptomatic_athlete_planning_return_to_sport
- Caution:return_to_competitive_endurance_only_after_3_to_6_mo_demonstrated_nsr_or_post_ablation_clearance (ESC 2020 Sports Cardiology PMID 32860412)

Monitoring

Regimen monitoring:
- continuous telemetry during acute phase
- echo at 3 and 6 months to assess chamber regression with detraining
- ambulatory holter 14 to 30d for af burden post cv or post ablation
- eGFR q3 to 6mo on doac (ESC 2024 PMID 39050851)
- sleep study if stop bang or nosas positive repeat post treatment
- training log quantification with athlete for volume reduction adherence
- symptom journal palpitations perceived exertion power output
- ablation outcome repeat eps or smartwatch at 3 and 12mo post procedure
- return to sport clearance after ett normal and no recurrence x 3 to 6mo (ESC 2020 PMID 32860412)

Setting (outpatient) monitoring:
- Quarterly cardiology + EP
- Echo q6-12 mo for chamber regression
- Smartwatch / Holter for AF burden q6 mo
- CHA2DS2-VASc + HAS-BLED annually
- eGFR q6m on DOAC

Follow-up plan: EP referral for early CTI ablation candidacy (typical AFL >95% acute success); cardiology q3 mo first year then q6-12 mo; sleep medicine if OSA positive; sport-medicine + cardiac rehab gradual return-to-training plan; AC reassessment annually per CHA2DS2-VASc; cardiac MRI surveillance if pathologic dilation suspected; consider LAAO if ablation refractory + AC contraindicated
- Close-out criterion: long-term EP + sport + AC + comorbid plan documented

Monitoring phase: 24-48 h telemetry if admitted; ambulatory rhythm monitor (Holter 14-30 d or smartwatch) for AF burden; surveillance echo at 3 + 6 mo for chamber regression with detraining; INR weekly if warfarin; eGFR q6mo on DOAC

Disposition

Current setting: outpatient — Long-term cardiology + sport-cardiology + EP coordination; post-ablation surveillance; return-to-competition decision; AC reassessment per CHA2DS2-VASc + sport-trauma; chamber regression surveillance with detraining; lifestyle anchor maintenance

Disposition criteria:
- Long-term continuation; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 for ablation pathway documentation; cross-link to cardio.afib.core.v1 if AF emerges; cross-link to cardio.acute-hf.core.v1 if persistent LV dysfunction from prior tachycardia-mediated CMP

Escalation triggers (move to higher acuity):
- Recurrent AFL post-ablation → re-ablation (CTI re-do success >90%)
- AF emergence (different mechanism) → PVI consideration
- Persistent LA dilation despite detraining 12 mo → cardiomyopathy workup (HCM, ARVC, sarcoid)
- Major bleed on AC → reverse + reassess long-term AC strategy
- Return-to-elite-competition request → individualized risk-benefit with sport-cardiology team per ESC 2020

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] WPW or pre-excitation pattern on resting ECG + flutter with ventricular rates >250 — risk of 1:1 conduction with ventricular pre-excitation degenerating to VF
- [SEVERE] Sustained AFL with rapid ventricular response (>130 sustained) + new severe LV dysfunction (EF <40) in previously high-functioning endurance athlete → tachycardia-mediated cardiomyopathy
- [SEVERE] AFL accompanied by syncope or pre-syncope — competition-related or training-related — must rule out concomitant channelopathy, HCM, ARVC, ischemia given young athlete sudden-death risk

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2024 AF (Van Gelder PMID 39050851) + ESC 2020 Sports Cardiology (Pelliccia PMID 32860412) + HRS/EHRA/ECAS 2017 Ablation Consensus (Calkins PMID 28506916) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 32860412) [PMID:32860412](https://pubmed.ncbi.nlm.nih.gov/32860412/)
- Cited evidence (PMID 28506916) [PMID:28506916](https://pubmed.ncbi.nlm.nih.gov/28506916/)
- Cited evidence (PMID 23736857) [PMID:23736857](https://pubmed.ncbi.nlm.nih.gov/23736857/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2024 AF (Van Gelder PMID 39050851) + ESC 2020 Sports Cardiology (Pelliccia PMID 32860412) + HRS/EHRA/ECAS 2017 Ablation Consensus (Calkins PMID 28506916) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 32860412) — PMID:32860412
  • Cited evidence (PMID 28506916) — PMID:28506916
  • Cited evidence (PMID 23736857) — PMID:23736857